Next Article in Journal
Assessment of the Extent of Resection in Surgery of High-Grade Glioma—Evaluation of Black Blood Sequences for Intraoperative Magnetic Resonance Imaging at 3 Tesla
Next Article in Special Issue
The Impact of the Ubiquitin System in the Pathogenesis of Squamous Cell Carcinomas
Previous Article in Journal
Cancer and SARS-CoV-2 Infection: Diagnostic and Therapeutic Challenges
Previous Article in Special Issue
Protein Stability of Pyruvate Kinase Isozyme M2 Is Mediated by HAUSP
Open AccessReview

Advances in Deubiquitinating Enzyme Inhibition and Applications in Cancer Therapeutics

1
Graduate School of Biomedical Science and Engineering, Hanyang University, Seoul 04763, Korea
2
College of Medicine, Hanyang University, Seoul 04763, Korea
*
Authors to whom correspondence should be addressed.
?
These authors contributed equally to this work.
Cancers 2020, 12(6), 1579; https://doi.org/10.3390/cancers12061579
Received: 24 April 2020 / Revised: 7 June 2020 / Accepted: 11 June 2020 / Published: 15 June 2020
(This article belongs to the Special Issue Targeting the Ubiquitin Pathway in Cancer)
Since the discovery of the ubiquitin proteasome system (UPS), the roles of ubiquitinating and deubiquitinating enzymes (DUBs) have been widely elucidated. The ubiquitination of proteins regulates many aspects of cellular functions such as protein degradation and localization, and also modifies protein-protein interactions. DUBs cleave the attached ubiquitin moieties from substrates and thereby reverse the process of ubiquitination. The dysregulation of these two paramount pathways has been implicated in numerous diseases, including cancer. Attempts are being made to identify inhibitors of ubiquitin E3 ligases and DUBs that potentially have clinical implications in cancer, making them an important target in the pharmaceutical industry. Therefore, studies in medicine are currently focused on the pharmacological disruption of DUB activity as a rationale to specifically target cancer-causing protein aberrations. Here, we briefly discuss the pathophysiological and physiological roles of DUBs in key cancer-related pathways. We also discuss the clinical applications of promising DUB inhibitors that may contribute to the development of DUBs as key therapeutic targets in the future. View Full-Text
Keywords: cancer therapy; deubiquitinase; DUB inhibitors; USPs phylogenetic tree; signaling pathways cancer therapy; deubiquitinase; DUB inhibitors; USPs phylogenetic tree; signaling pathways
Show Figures

Figure 1

MDPI and ACS Style

Antao, A.M.; Tyagi, A.; Kim, K.-S.; Ramakrishna, S. Advances in Deubiquitinating Enzyme Inhibition and Applications in Cancer Therapeutics. Cancers 2020, 12, 1579.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop 宝马游戏手机网站 体彩排三专家预测推荐 35选7好运4开奖结果 股票软件排行榜前十名 好运彩字谜 云南期货配资公司 北京pk10官网开奖视频 秒速时时彩开奖网站 11选5电视图表 山西11选五前3走势图 浙江省体彩6+1开奖结果查询 三分PK拾怎么做计划 上证指数走势图如何看 三肖默认版块discuz网站多少 南大光电股票代码 今日福建十一选五走势 金来源配资